Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blinded, Placebo-controlled, Single Ascending Dose, Two-part, Randomized, Phase 2 Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BB-031 in Acute Ischemic Stroke Patients

NCT06226805 is registered in ClinicalTrials.gov with Basking Biosciences, Inc. as lead sponsor.

NCT NCT06226805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06226805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blinded, Placebo-controlled, Single Ascending Dose, Two-part, Randomized, Phase 2 Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BB-031 in Acute Ischemic Stroke Patients
Lead sponsor
Basking Biosciences, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 31, 2024
Completion date
September 30, 2027
Enrollment
228 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke